Synthesis of multivalent sialyllactosamine-carrying glyco-nanoparticles with high affinity to the human influenza virus hemagglutinin

Multivalent Peptide–Nanoparticle Conjugates for Influenza‐Virus Inhibition

“…High molecular‐weight scaffolds displaying a large number of low affinity SA derived ligands were used to achieve high HA avidity. Over the years several carrier systems were employed as scaffolds ranging from polymers,6, 8, 9 dendrimers,10, 11, 12, 13 liposomes,5, 14 proteins,15 to gold nanoparticles 16. The most affine binders reported to date consist of SA tethered to linear polyacrylamide polymers 6.…”

Glycomacromolecules: Addressing challenges in drug delivery and therapeutic development

“…199 The influenza hemagglutinin is another key therapeutic target. A number of multivalent inhibitors have been designed on macromolecular scaffolds including polymers, [200][201][202][203] nanoparticles, 204,205 dendrimers, 206 and virus-like particles, 207,208 exploiting cluster glycoside effects to enable improvements in potency. In some cases, these glycomacromolecules present promising new drug candidates, in addition to presenting the opportunity to develop multi-function drug delivery systems that could inhibit key therapeutic viral targets, and co-administer other therapeutics to infected tissue.…”

Nanotechnology and sialic acid biology

“…Sialoglyco-conjugated NPs synthesized from highly branched αglucuronic acid-linked cyclic dextrins (GlcA-HBCD) forming sialoglyco-NP (Neu5Acα2,6LacNAc-GlcA-HBCDs, sialoglycoNP [SAGNP]) could recognize and interact with human influenza virus strain A/Beijing/262/95 (H1N1) detected by HA inhibition assay and SAG-NP with sialic acid substitution of 30, have been reported to inhibit virus-binding activity [86].…”